Oeckl et al.21 used Quanterix Simoa GFAP Discovery kit to measure serum GFAP and observed a 2-fold increase in Alzheimer’s disease (n = 230) group compared with the behavioural frontotemporal dementia group (n = 140, P < 0.001) and controls (n = 129, P < 0.001). This evidence concerns the gene GFAP and Alzheimer disease.